Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder
A Multi-Center, Randomised, Parallel Group, Double-Blind, Placebo Controlled Estimation Study To Assess The Efficacy And Safety Of Modified Release UK-369,003 In The Treatment Of Men With Storage Lower Urinary Tract Symptoms (LUTS) With And Without Erectile Dysfunction (ED).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New South Wales
-
Miranda, New South Wales, Australia, 2228
- Pfizer Investigational Site
-
-
Queensland
-
Kippa Ring, Queensland, Australia, 4021
- Pfizer Investigational Site
-
-
-
-
British Columbia
-
Victoria, British Columbia, Canada, V8T 5G1
- Pfizer Investigational Site
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 7G1
- Pfizer Investigational Site
-
Kitchener, Ontario, Canada, N2N 2B9
- Pfizer Investigational Site
-
Toronto, Ontario, Canada, M6A 3B5
- Pfizer Investigational Site
-
-
-
-
RM
-
Santiago, RM, Chile, 8380419
- Pfizer Investigational Site
-
Santiago, RM, Chile, 8380456
- Pfizer Investigational Site
-
-
VI Región
-
Rancagua, VI Región, Chile, 2820945
- Pfizer Investigational Site
-
-
-
-
Antioquia
-
Medellin, Antioquia, Colombia
- Pfizer Investigational Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia
- Pfizer Investigational Site
-
-
-
-
-
Helsinki, Finland, 00100
- Pfizer Investigational Site
-
Kouvola, Finland, 45200
- Pfizer Investigational Site
-
Oulu, Finland, 90100
- Pfizer Investigational Site
-
Tampere, Finland, 33100
- Pfizer Investigational Site
-
Turku, Finland, 20100
- Pfizer Investigational Site
-
-
-
-
-
Garches, France, 92380
- Pfizer Investigational Site
-
Lyon Cedex 03, France, 69437
- Pfizer Investigational Site
-
Montpellier, France, 34090
- Pfizer Investigational Site
-
Paris, France, 75020
- Pfizer Investigational Site
-
Rennes Cedex 9, France, 35033
- Pfizer Investigational Site
-
-
-
-
-
Frankfurt, Germany, 65929
- Pfizer Investigational Site
-
Marburg, Germany, 35039
- Pfizer Investigational Site
-
Muelheim a.d. Ruhr, Germany, 45468
- Pfizer Investigational Site
-
Muenchen, Germany, 81925
- Pfizer Investigational Site
-
Rosenheim, Germany, 83022
- Pfizer Investigational Site
-
-
-
-
Athens
-
Holargos, Athens, Greece, 15562
- Pfizer Investigational Site
-
-
Ioannina
-
Epirus, Ioannina, Greece, 45500
- Pfizer Investigational Site
-
-
Patras
-
Rio, Patras, Greece, 26500
- Pfizer Investigational Site
-
-
-
-
-
Firenze, Italy, 50139
- Pfizer Investigational Site
-
Latina, Italy, 04100
- Pfizer Investigational Site
-
-
Palermo
-
Cefalu', Palermo, Italy, 90015
- Pfizer Investigational Site
-
-
-
-
-
Riga, Latvia, LV 1010
- Pfizer Investigational Site
-
-
-
-
-
Moelv, Norway, N-2390
- Pfizer Investigational Site
-
Oslo, Norway, NO-0257
- Pfizer Investigational Site
-
-
-
-
-
Myslowice, Poland, 41-400
- Pfizer Investigational Site
-
Poznan, Poland, 61-485
- Pfizer Investigational Site
-
Szczecin, Poland, 70-111
- Pfizer Investigational Site
-
Szczecin, Poland, 70-451
- Pfizer Investigational Site
-
Szczecin, Poland, 70-467
- Pfizer Investigational Site
-
Wroclaw, Poland, 53-020
- Pfizer Investigational Site
-
-
-
-
-
Bratislava 37, Slovakia, 833 31
- Pfizer Investigational Site
-
Kosice, Slovakia, 040 11
- Pfizer Investigational Site
-
Martin, Slovakia, 036 59
- Pfizer Investigational Site
-
Trencin, Slovakia, 911 01
- Pfizer Investigational Site
-
-
-
-
Barcelona
-
Sabadell, Barcelona, Spain, 08208
- Pfizer Investigational Site
-
-
Palma de Mallorca
-
Manacor, Palma de Mallorca, Spain, 07500
- Pfizer Investigational Site
-
-
-
-
-
Aarau, Switzerland, 5001
- Pfizer Investigational Site
-
Zurich, Switzerland, 8091
- Pfizer Investigational Site
-
-
-
-
-
Leeds, United Kingdom, LS9 7TF
- Pfizer Investigational Site
-
-
Newcastle upon Tyne
-
High Heaton, Newcastle upon Tyne, United Kingdom, NE7 7DN
- Pfizer Investigational Site
-
-
Somerset
-
Taunton, Somerset, United Kingdom, TA1 5DA
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male subjects aged 18 years and above
- documented clinical diagnosis of overactive bladder with urinary frequency >= 8 times / 24 hours and number of urgency episodes > 1 episode / 24 hours.
Exclusion Criteria:
- Neurological diseases known to affect bladder function.
- Urinary tract infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo
|
|
Experimental: Active
|
UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
This is an estimation study with no primary endpoint. There are efficacy endpoints.
Time Frame: 12 Weeks
|
12 Weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Patient reported treatment impact questionnaire.
Time Frame: 12 Weeks
|
12 Weeks
|
|
Lower urinary tract symptoms diary.
Time Frame: 12 Weeks
|
12 Weeks
|
|
International prostate symptom score questionnaire.
Time Frame: 12 Weeks
|
12 Weeks
|
|
OAB-q short form questionnaire.
Time Frame: 12 Weeks
|
12 Weeks
|
|
Patient perception of bladder control questionnaire.
Time Frame: 12 Weeks
|
12 Weeks
|
|
International index of erectile function questionnaire.
Time Frame: 12 Weeks
|
12 Weeks
|
|
International consultation on incontinence questionnaire.
Time Frame: 12 Weeks
|
12 Weeks
|
|
Quality of erection questionnaire.
Time Frame: 12 Weeks
|
12 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A3711047
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.